Steris narrows FY25 adjusted EPS view to $9.05-$9.15 from $9.05-$9.25

Consensus $9.06. Lowers FY25 revenue view to up 6% from up 6.5%-7.5%. The company said, “For fiscal 2025, the Company now expects as reported revenue to increase approximately 6% compared with prior expectations of 6.5% to 7.5%. This change is primarily due to currency, as forward rates through March 31, 2025, are now expected to be unfavorable to revenue in fiscal 2025, as well as lower than anticipated revenue for capital equipment in the Healthcare segment. Constant currency organic revenue from continuing operations is also now anticipated to be approximately 6%, compared with prior expectations of 6% to 7%. Adjusted earnings per diluted share from continuing operations is anticipated to be in the range of $9.05 to $9.15 compared with prior expectations of $9.05 to $9.25, mainly driven by an approximately ten cent negative impact from currency. The fiscal 2025 outlook assumes an effective tax rate of approximately 23%. Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 million. This outlook does not reflect any potential impact from new tariffs.”